Trial Profile

A Single-arm, Open-label, Phase Ⅱ Clinical Trial of Anti-PD-1 Antibody SHR-1210 or Anti-PD-L1 Antibody SHR-1316 Combined With Apatinib Mesylate as a Second-line Treatment for Advanced Esophageal Squamous Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adebrelimab (Primary) ; Camrelizumab (Primary) ; Rivoceranib (Primary) ; SHR-A2009 (Primary)
Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

19 Sep 2024 Number of treatment arms are increased from 3 to 4 by the addition of Experimental arm Cohort: SHR-1316 (Adebrelimab)+SHR-A2009.
19 Sep 2024 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.
19 Sep 2024 Planned number of patients changed from 125 to 147.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com